ClinicalTrials.gg
CompletedNCT05213728(VXA-G1-1-NN)Updated Jun 21, 2024

A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

A Phase 1 interventional study of VXA-G1.1-NN in Norovirus Infections, sponsored by Vaxart. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by Vaxart · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Feb 2022, 4 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Caliciviridae Infections with a site in United States — none open to participants now, none under way, none of them phase 3. Caliciviridae Infections · United States.

Enrollment
10th of 11
8 · median 60
Started
2022
the only one that year
Phase 1
6 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
7 of 11
Vaxart

Among the 11 studies in Caliciviridae Infections with a site in United States, this one is the 10th largest by enrollment, is the only one that started in 2022, is one of 6 in phase 1, and was the 8th registered.

Caliciviridae Infections

20 studies on the registry are indexed under Caliciviridae Infections; 2 are open to participants now.

Browse Caliciviridae Infections studies →

Open to participants now

None of the 11 studies in Caliciviridae Infections with a site in United States is open now. The open studies under Caliciviridae Infections, anywhere →

Who these studies take

Of the 2 Caliciviridae Infections studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Caliciviridae Infections with a site in United States as a file.
02

Study summary

Subjects will receive multiple sub-doses over a 4-hour period to deliver a total overall dose of 1E11. Evaluations of immunogenicity, safety, and tolerability will be evaluated. The active period consists of data collection at Day 1, Day 8, and Day 29. Safety follow-up continues by phone screen at Day 180 and Day 365.

Read the detailed description

Primary Objective

  • To determine the immunogenicity of the VXA-G1.1-NN oral vaccine administered via multiple sub-doses over a 4-hour period to deliver a total dose of

    1E11 IU ±0.5 log Secondary Objectives

  • To determine the safety and tolerability of the VXA-G1.1-NN oral vaccine administered via multiple sub-doses over a 4-hour period to deliver a total dose of 1E11 IU ±0.5 log

This is an open-label study in healthy adult participants aged 18-55 years old. The study will enroll 8 subjects to a single treatment cohort, all of whom will receive a single 1E11 IU± 0.5 log at Day 1. This dose will be administered in a step wise manner over 4 hours with 1/3 of the dose administered at T=0, 1/3 of the dose administered at T= 2 hours and 1/3 of the dose administered at T=4 hours.

The study will include a Screening Period, Active Period (Day 1 to Day 29, 4 weeks post vaccination) and a Safety Follow-up Period through 12 months post vaccination (Day 365). In addition, participants will be contacted by phone during the Safety Follow-up Period to assess for Serious Adverse Events (SAEs), AEs of Special Interest (AESIs) and New Onset of Chronic Illness (NOCIs).

After signing an informed consent, participants will undergo screening assessments to determine study eligibility within a 30-day screening period. Eligible participants will be enrolled and receive their first dose of study vaccine on Day 1.

During the Active Period, participants will record any potential solicited symptoms of reactogenicity daily for 1 week post study vaccination. Participants will return to the site as specified in the Schedule of Activities to have safety assessments and samples collected for evaluation of immunogenicity. Approximately 8 subjects will be vaccinated in the active phase.

The following study visits and remote contacts will be conducted during the study:

Active Period:

  • Screening Period (Days -30 to -1)
  • Day 1 Visit (Baseline assessments, vaccination, sample collection)
  • Day 8 Visit (Safety assessments, sample collection)
  • Day 29 End of Active Period; (Safety assessments, sample collection)

Safety Follow-Up Period:

  • Day 180 (follow-up phone call for safety)
  • Day 365 (follow-up phone call for safety): Study completion
03

Conditions studied

  • Norovirus Infections
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 55 years old, inclusive, at day of signing Form (ICF)
  2. General good health, without significant uncontrolled medical illness, based on medical history, physical examination, vital signs, and clinical laboratories (CBC, chemistry, and urinalysis) as determined by the investigator in consultation with the Research Monitor and Sponsor
  3. (BMI) between 17 and 35 kg/m2 at screening
  4. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol
  5. Available for all planned visits and phone calls, and willing to complete all protocol-defined procedures and assessments (including ability and willingness to swallow multiple small enteric-coated tablets per study dose)
  6. Female participants must provide a negative pregnancy test at each required visit and fulfill one of the following criteria:

    1. At least 1 year (defined as amenorrhea for ≥12 consecutive months prior to Screening without alternative medical cause)
    2. Surgically sterile
    3. Use of oral, implantable, transdermal or injectable for 30 days prior to initial vaccination and until 60 days after the last vaccination. The form of contraception must be approved by the Investigator
    4. A reliable form of contraception must be approved by the Investigator (e.g., double barrier method, Depo-Provera, intrauterine device, Norplant, oral contraceptives, contraceptive patches)
    5. Not be sexually active (abstinent) or be in a relationship with partner who is sterile (must be discussed with site staff and documented)
  7. Male participants must agree not to father a child or donate sperm, as well as to use contraception/barrier (a male condom) or be abstinent from heterosexual intercourse during the study active period (Day 29)

Exclusion criteria

Exclusion Criteria:

  1. Presence of significant uncontrolled medical or psychiatric illness (acute or chronic) including institution of new medical/surgical treatment or significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months of screening and reconfirmed at baseline
  2. Cancer, or received treatment for cancer, within past 3 years (excluding basal cell carcinoma or squamous cell carcinoma)
  3. Presence of or medical condition possibly associated with impaired immune responsiveness, including diabetes mellitus 1 and 2
  4. History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine Norwalk GI.1 (VXA-G1.1-NN) Protocol No. VXA-NVV-106

    ________________________________________________________________________________

    _________________________________________________________________________________ Version 1.2 Confidential Page 11 of 42 Date: 04 Jan 2022

    Such conditions may include but are not limited to:

    1. Esophageal Motility Disorder
    2. Malabsorption
    3. Pancreaticobiliary disorders
    4. Irritable bowel syndrome
    5. Inflammatory Bowel Disease
    6. Surgical Resection
    7. GERD
    8. Hiatal Hernia
    9. Peptic Ulcer (History of cholecystectomy is not exclusionary)
  5. History of any form of angioedema
  6. History of serious reactions to any vaccination such as anaphylaxis, respiratory problems, hives or abdominal pain
  7. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that could make blood draws problematic
  8. Any condition that resulted in the absence or removal of the spleen
  9. Acute disease within 72 hours prior to vaccination defined as the presence of a moderate or severe illness (as determined by the Investigator through medical history and physical exam); assessment may be repeated during screening period
  10. Presence of a fever ≥ 38oC measured orally at baseline; assessment may be repeated during screening period
  11. Laboratory values outside the range of normal for counts and the following coagulation tests: , aPTT and fibrinogen
  12. Any of the following history or conditions that may lead to higher risk of clotting events and/or thrombocytopenia:

    1. Family or personal history of bleeding or thrombosis
    2. History of heparin-related thrombotic events, and/or receiving heparin treatments
    3. History of or inflammatory disease
    4. Presence of any of the following conditions known to increase risk of thrombosis within 6 months prior to screening:

      • Recent surgery other than removal/ of cutaneous lesions
      • Immobility (confined to bed or wheelchair for 3 or more successive days)
      • Head trauma with loss of consciousness or documented brain injury
      • Receipt of anticoagulants for prophylaxis of thrombosis
      • Recent infection
  13. Any significant hospitalization within the last year which in the opinion of Norwalk GI.1 (VXA-G1.1-NN) Protocol No. VXA-NVV-106
  14. Any other condition that in the clinical judgment of the investigator would jeopardize the safety or rights of a participant taking in the study, would render the participant unable to comply with the protocol or would interfere with the evaluation of the study endpoints
  15. Positive (HIV), surface antigen (HBsAg) or virus (HCV) tests at screening visit
  16. Positive urine drug screen for drugs of abuse at screening
  17. Positive breath or urine alcohol test at screening and baseline
  18. Receipt of a licensed vaccine within 14 days prior to baseline vaccination or planned administration during the study active period
  19. Use of antibiotics, proton pump inhibitors, H2 blockers or antacids within 7 days prior to study drug administration or planned use during the active study period
  20. Use of medications known to affect the immune function (e.g., systemic and others) within 2 weeks before study vaccination or planned use during the active period
  21. Daily use of nonsteroidal anti-inflammatory drugs within 7 days prior to study vaccination or planned use during the active study period
  22. Administration of any vaccine, drug or device within 8 weeks preceding study vaccination (Day 1), or planned use within the duration of the study
  23. Donation or use of blood or blood products within 30 days prior to study vaccination or planned donation during the active study period
  24. History of drug, alcohol or chemical abuse within 1 year of screening
  25. History of or allergic reaction to any component of the investigational vaccine, including but not limited to fish gelatin
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Single 1E11 dose administered via multiple sub-doses over a 4-hour period in adults (18-55 yrs).

    Biological: VXA-G1.1-NN

Interventions

  • BiologicalVXA-G1.1-NN

    Norovirus GI.1 Norwalk VP1 Vaccine (VXA-G1.1-NN) E1/E3-Deleted Replication-Defective Recombinant Adenovirus 5 with Adjuvant Oral Tablet Vaccine.

    Also known as: Oral Tableted Ad5 Norovirus GI.1 Vaccine

06

What researchers measure

Primary outcomes

  1. Rate of Solicited Symptoms of Reactogenicity

    To assess the safety and tolerability of an oral tableted vaccine by collection of solicited symptoms of vaccine reactogenicity recorded daily using a subject diary card for 1 week post initial vaccination at Day 1.

    Time frame: Up to Day 8

  2. To assess the induction of VP1-specific Immunoglobin A (IgA) antibody-secreting cells (ASC) by ELISpot assay

    Change from baseline in VP1-specific Immunogolobin A (IgA) antibody-secreting cells (ASC) by ELISpot assay will be evaluated at Day 8

    Time frame: Change from baseline at Day 8

  3. To assess histo-blood group antigen (HBGA) blocking antibodies by blockade titer (BT50)

    Change from baseline in histo-blood group antigen (HBGA) blocking antibodies evaluated at Day 29

    Time frame: Change from baseline at Day 29

  4. To assess VP1-specific serum Immunoglobin G (IgG) by Mesoscale Discovery (MSD) assay

    Change from baseline in VP1-specific Immunoglobin G (IgG) by Mesoscale Discovery (MSD) assay will be evaluated at Day 29

    Time frame: Change from baseline at Day 29

  5. To assess the VP1-specific serum Immunoglobin A (IgA) by Mesoscale Discovery (MSD) assay

    Change from baseline in VP1-specific serum IgG by Mesoscale Discovery (MSD) will be evaluated at Day 29

    Time frame: Change from baseline at Day 29

07

Study locations

1 site
  • AltaSciences LA
    Cypress, California 90630, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Feb 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2022
First posted
Jan 28, 2022
StartActual
Jan 24, 2022
Primary completionActual
Feb 1, 2022
CompletionActual
Feb 24, 2022
Last update
Jun 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05213728
Lead sponsor
Vaxart
Responsible party
Sponsor
First posted
Jan 28, 2022
Start date
Jan 24, 2022
Primary completion
Feb 1, 2022
Completion
Feb 24, 2022
Last update
Jun 21, 2024

Study contacts

James Cummings, MD
study director · Vaxart, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VXA-G1.1-NN

Start the discussion